Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$28 Mln
P/E Ratio
--
P/B Ratio
3.63
Industry P/E
--
Debt to Equity
1.25
ROE
-10.39 %
ROCE
-215.11 %
Div. Yield
0 %
Book Value
1.28
EPS
-4.84
CFO
$-168.19 Mln
EBITDA
$-231.50 Mln
Net Profit
$-202.86 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
PolyPid (PYPD)
| -10.86 | -3.56 | -16.62 | -38.41 | -73.69 | -- | -- |
|
BSE Sensex*
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
|
|---|---|---|---|
|
PolyPid (PYPD)
| -81.84 | -87.84 | -42.02 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 6.47 | 377.68 | 25.6 | 5.74 | |
| 17.95 | 190.76 | -- | -96.33 | |
| 2.24 | 3.96 | -- | -321.92 |
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its... lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. Address: 18 Hasivim Street, Petah Tikva, Israel, 4959376 Read more
CEO & Director
Ms. Dikla Czaczkes Akselbrad
CEO & Director
Ms. Dikla Czaczkes Akselbrad
Headquarters
Petah Tikva
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of PolyPid (PYPD) stood at $ 25 Mln as on 31-Dec-24
The share price of PolyPid (PYPD) is $2.71 (NASDAQ) as of 22-Apr-2025 16:00 EDT. PolyPid (PYPD) has given a return of -73.69% in the last 3 years.
PolyPid (PYPD) has a market capitalisation of $ 28 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of PolyPid (PYPD) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the PolyPid (PYPD) and enter the required number of quantities and click on buy to purchase the shares of PolyPid (PYPD).
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. Address: 18 Hasivim Street, Petah Tikva, Israel, 4959376
The CEO & director of Ms. Dikla Czaczkes Akselbrad. is PolyPid (PYPD), and CFO & Sr. VP is Ms. Dikla Czaczkes Akselbrad.
There is no promoter pledging in PolyPid (PYPD).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
35
|
|
|
19
|
|
|
0
|
|
|
35
|
| PolyPid (PYPD) | Ratios |
|---|---|
|
Return on equity(%)
|
-1038.73
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of PolyPid (PYPD) was $0 Mln.
$-0.04
(
